RAD51D and breast carcinoma: The estimated cumulative risks of developing tubo-ovarian carcinoma and breast cancer to age 80 years were 13% (95% CI: 7–23%) and 20% (95% CI: 14–28%) for RAD51D pathogenic variant carriers [12].